LONDON (Alliance News) - ReNeuron Group PLC said Thursday that it has received final regulatory and ethical approvals to begin two new clinical trials using its CTXcyro stem cell product.
The company will begin a Phase II clinical trial of its ReN001 investigational therapy in stroke disability, and a Phase I clinical trial of its ReN009 therapy in critical limb ischaemia, a condition which restricts blood supply to tissues.
ReNeuron said that these regulatory approvals allow it to deploy the CTXcryo stem cells in clinical development earlier than planned.
Shares in ReNeuron were trading up 5.4% at 3.37 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)